Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Chinese Adults With Moderate to Severe Hidradenitis Suppurativa
NCT07489573Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 4, open-label trial of secukinumab in hidradenitis suppurativa (HS) (2 arms), sponsored by Novartis. Primary endpoint: Hidradenitis Suppurativa Clinical Response 50 at 16 weeks. Started Jun 2026; status: recruiting.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07489573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489573.